Smith Katzenstein & Jenkins LLP

Delaware

General

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Cases222

Challenger50%

Patent Owner50%

NPE50%

smith-katzenstein

skjlaw.com

Practice Areas

BiotechComp. Arch. and SoftwareCommunications

Top Attorneys

Patrick J. CoyneNeal S. CohenPeter Kinsella

Elite Ratings

DCTPTABCAFC

Ratings

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Experience

Grade

Trend

DCT

PTAB

CAFC

Analytics

Lawyers

Cases

Ratings Trends

Practice Areas

Recent Dockets

Entered	Case	Description
09/16/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	REDACTED VERSION of [287] Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # [1] Exhibit G, # [2] Exhibit H, # [3] Exhibit I)(Gattuso, Dominick) (Entered: 09/16/2024)
09/16/24	Abbvie Inc v. Alkem Laboratories Ltd 1:22-CV-01423 ( D. DE )	SO ORDERED, re [273] Stipulation and Order to Extend Expert Reports and Daubert Motions Deadlines. (Reset Scheduling Order Deadlines: Opening Expert Reports due by 11/14/2024; Rebuttal Expert Reports due by 1/23/2025; Reply Expert Reports due by 2/14/2025; Close of Expert Discovery on 4/10/2025; Daubert Motions due by 4/17/2025). Signed by Judge Jennifer L. Hall on 9/16/2024. (ceg) (Entered: 09/16/2024) SO ORDERED, re [273] Stipulation and Order to Extend Expert Reports and Daubert Motions Deadlines. (Reset Scheduling Order Deadlines: Opening Expert Reports due by 11/14/2024; Rebuttal Expert Reports due by 1/23/2025; Reply Expert Reports due by 2/14/2025; Close of Expert Discovery on 4/10/2025; Daubert Motions due by 4/17/2025). Signed by Judge Jennifer L. Hall on 9/16/2024. (ceg) (Entered: 09/16/2024)
09/16/24	In re: Entresto (Sacubitril/Valsartan) Patent Litigation 1:20-MD-02930 ( D. DE )	REDACTED VERSION of [1528] Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # [1] Exhibit G, # [2] Exhibit H, # [3] Exhibit I)(Gattuso, Dominick) (Entered: 09/16/2024)
09/16/24	In re: Xarelto (Rivaroxaban) ('310) Patent Litigation 1:21-MD-03017 ( D. DE )	REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [297] . (nms) (Entered: 09/16/2024)
09/16/24	In re: Entresto (Sacubitril/Valsartan) Patent Litigation 1:20-MD-02930 ( D. DE )	DEFICIENCY NOTICE by the Court issued to Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co. Limited re [1539] Redacted Document. Upon review it was determined this filing was not a complete version of what was filed at D.I. [1528] . The redaction lacked Exhibit I. Defendants are to file a revised redacted version of D.I. [1528] no later than three (3) days from the date of this notice. (nms) (Entered: 09/16/2024) DEFICIENCY NOTICE by the Court issued to Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co. Limited re [1539] Redacted Document. Upon review it was determined this filing was not a complete version of what was filed at D.I. [1528] . The redaction lacked Exhibit I. Defendants are to file a revised redacted version of D.I. [1528] no later than three (3) days from the date of this notice. (nms) (Entered: 09/16/2024)
09/16/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	DEFICIENCY NOTICE by the Court issued to Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co. Limited re [296] Redacted Document. Upon review it was determined this filing was not a complete version of what was filed at D.I. [287] . The redaction lacked Exhibit I. Defendants are to file a revised redacted version of D.I. [287] no later than three (3) days from the date of this notice. (nms) (Entered: 09/16/2024) DEFICIENCY NOTICE by the Court issued to Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co. Limited re [296] Redacted Document. Upon review it was determined this filing was not a complete version of what was filed at D.I. [287] . The redaction lacked Exhibit I. Defendants are to file a revised redacted version of D.I. [287] no later than three (3) days from the date of this notice. (nms) (Entered: 09/16/2024)
09/13/24	Truinject Corp v. Galderma SA 1:19-CV-00592 ( D. DE )	[SEALED] MEMORANDUM AND ORDER re : Plaintiffs Motion to Strike (D.I. 803) is GRANTED-IN PART and DENIED-IN PART as set forth herein. Defendants' Motion for Summary Judgment on Plaintiffs Remaining Claims (D.I.829) is GRANTED. Defendant's Motion to Exclude Certain Expert Testimony of Mr. Saul Solomon (D.I.593) is granted-in-part and denied-in-part as described herein. Plaintiffs Motion for Leave to Serve a Supplemental Report of Plaintiffs Damages Expert (D.I. 832), Defendants' Motion for Leave to File a Sur-Reply in Opposition to Plaintiffs Motion for Leave (D.I. 863), and Plaintiffs Motion to Set a Trial Date (D.I. 865) are DENIED AS MOOT. By no later than September 20, 2024, the parties shall meet and confer and submit a joint status report setting out what issues remain for resolution by the Court. Because this opinion is filed under seal, the parties shall meet and confer and, no later than September 20, 2024, submit a joint proposed redacted version. In the absence of a timely request compliant with applicable standards, the Court with unseal the entire Order. Signed by Judge Gregory B. Williams on 9/13/24.This order has been emailed to local counsel. (jaa) (Entered: 09/13/2024) [SEALED] MEMORANDUM AND ORDER re : Plaintiffs Motion to Strike (D.I. 803) is GRANTED-IN PART and DENIED-IN PART as set forth herein. Defendants' Motion for Summary Judgment on Plaintiffs Remaining Claims (D.I.829) is GRANTED. Defendant's Motion to Exclude Certain Expert Testimony of Mr. Saul Solomon (D.I.593) is granted-in-part and denied-in-part as described herein. Plaintiffs Motion for Leave to Serve a Supplemental Report of Plaintiffs Damages Expert (D.I. 832), Defendants' Motion for Leave to File a Sur-Reply in Opposition to Plaintiffs Motion for Leave (D.I. 863), and Plaintiffs Motion to Set a Trial Date (D.I. 865) are DENIED AS MOOT. By no later than September 20, 2024, the parties shall meet and confer and submit a joint status report setting out what issues remain for resolution by the Court. Because this opinion is filed under seal, the parties shall meet and confer and, no later than September 20, 2024, submit a joint proposed redacted version. In the absence of a timely request compliant with applicable standards, the Court with unseal the entire Order. Signed by Judge Gregory B. Williams on 9/13/24.This order has been emailed to local counsel. (jaa) (Entered: 09/13/2024)
09/12/24	Ingenus Pharmaceuticals LLC v. Hetero USA Inc 1:24-CV-01025 ( D. DE )	SUMMONS Returned Executed by Ingenus Pharmaceuticals, LLC.Hetero USA, Inc. served on 9/12/2024, answer due 10/3/2024. (Taylor, Daniel) (Entered: 09/12/2024)
09/12/24	Abbvie Inc v. DR Reddys Laboratories Ltd 1:20-CV-00968 ( D. DE )	ORDER, Counsel shall meet and confer and shall jointly file a proposed scheduling order for the Court's consideration by September 27, 2024. This order shall include the dates for the final pre-trial order, the pre-trial conference, trial, and the parties' modified plan to simplify this matter (narrowing of claims) as discussed in the conference. Additionally, it is ORDERED that the final pre-trial order shall contained the parties' understanding of this case's preclusive effect on claims asserted in the complaint, but not litigated at trial. Signed by Judge Mitchell S. Goldberg on 9/12/2024. (jfm) (Entered: 09/12/2024) ORDER, Counsel shall meet and confer and shall jointly file a proposed scheduling order for the Court's consideration by September 27, 2024. This order shall include the dates for the final pre-trial order, the pre-trial conference, trial, and the parties' modified plan to simplify this matter (narrowing of claims) as discussed in the conference. Additionally, it is ORDERED that the final pre-trial order shall contained the parties' understanding of this case's preclusive effect on claims asserted in the complaint, but not litigated at trial. Signed by Judge Mitchell S. Goldberg on 9/12/2024. (jfm) (Entered: 09/12/2024)
09/13/24	Abbvie Inc v. DR Reddys Laboratories Ltd 1:20-CV-00968 ( D. DE )	Minute Entry for proceedings held before Judge Mitchell S. Goldberg - Status Conference held on 9/12/2024. Plaintiffs' Counsel: Chad J. Peterman and Michelle Streifthau-Livizos. Defenses' Counsel: Neal Belgam, Brandon White, Daniel Tayler, Anne Shea Gaza, Adam C. LaRock, and Samantha G. Wilson. (Court Reporter Maureen McHugh.) (mpb) (Entered: 09/13/2024)